Receipt of more chemotherapy (38% vs 29%), surgery (9% vs 6.9%), chemoradiation (12% vs 9.2%), and multimodal treatment (21% vs 15%) was seen in patients with EOPC. Higher 1-year overall survival was observed EOPC vs AOPC across each stage and treated patients. Findings revealed that more oncologic therapy was received by patients with EOPC vs those with AOPC, although NCDB did not provide information regarding the intensity, type, and duration of chemotherapy; however, no therapy was received by 19% and 39%, respectively. Read more . . .
Researchers used the National Cancer Data Base (NCDB) to assess treatment utilization for early-onset pancreatic cancer (EOPC) compared with average-age-onset pancreatic cancer (AOPC). They also investigated factors linked with failure to receive treatment. Participants were patients with EOPC (age < 50 years) or AOPC (age ≥ 50 years). EOPC was present in 15,710 (6.3%) of 248,634 patients.